John Choi

ORCID: 0000-0002-2861-0180
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Acute Lymphoblastic Leukemia research
  • Acute Myeloid Leukemia Research
  • Lymphoma Diagnosis and Treatment
  • Adrenal and Paraganglionic Tumors
  • Chronic Lymphocytic Leukemia Research
  • Cancer, Hypoxia, and Metabolism
  • Glioma Diagnosis and Treatment
  • Immune Cell Function and Interaction
  • Childhood Cancer Survivors' Quality of Life
  • Cutaneous lymphoproliferative disorders research
  • CAR-T cell therapy research
  • Platelet Disorders and Treatments
  • CNS Lymphoma Diagnosis and Treatment
  • Hemoglobinopathies and Related Disorders
  • Chronic Myeloid Leukemia Treatments
  • Viral-associated cancers and disorders
  • Epigenetics and DNA Methylation
  • Eosinophilic Disorders and Syndromes
  • Erythrocyte Function and Pathophysiology
  • Histiocytic Disorders and Treatments
  • Sarcoma Diagnosis and Treatment
  • Neuroblastoma Research and Treatments
  • Protein Degradation and Inhibitors
  • Muscle Physiology and Disorders
  • Cell Adhesion Molecules Research

St. Jude Children's Research Hospital
2014-2025

University of Alabama at Birmingham
2020-2025

Western University
2024

Korea Advanced Institute of Science and Technology
2024

University of Alberta
2024

University of Tennessee Health Science Center
2014-2023

University of Calgary
2020-2021

Sidney Kimmel Comprehensive Cancer Center
2021

Johns Hopkins University
2021

Johns Hopkins Medicine
2021

Histiocytic neoplasms are clonal, hematopoietic disorders characterized by an accumulation of abnormal, monocyte-derived dendritic cells or macrophages in Langerhans cell histiocytosis (LCH) and non-Langerhans (non-LCH), respectively. The discovery BRAF(V600E) mutations approximately 50% these patients provided the first molecular therapeutic target histiocytosis. However, recurrent driving majority with BRAF(V600E)-wild-type non-LCH unknown, cooperating non-MAP kinase pathways undefined for...

10.1158/2159-8290.cd-15-0913 article EN Cancer Discovery 2015-11-14

The present research uncovers the dynamic nature of student discipline. findings show that discipline escalates during school year, more severely for Black students, and racial disparities in ...Researchers have long used end-of-year rates to identify punitive schools, explore sources inequitable treatment, evaluate interventions designed stem both Yet, this approach leaves us ...

10.1073/pnas.87.20.7988 article EN Proceedings of the National Academy of Sciences 1990-10-01

Despite contemporary treatment, up to 10% of children with acute lymphoblastic leukemia still experience relapse. We evaluated whether a higher dosage PEG-asparaginase and early intensification triple intrathecal therapy would improve systemic CNS control.

10.1200/jco.19.01692 article EN Journal of Clinical Oncology 2019-10-28

Abstract We evaluated clinical significance of recently identified subtypes acute lymphoblastic leukemia (ALL) in 598 children treated with minimal residual disease (MRD)–directed therapy. Among the 16 B-cell ALL (B-ALL) and 8 T-cell by next-generation sequencing, ETV6–RUNX1, high-hyperdiploid, DUX4-rearranged B-ALL had best 5-year event-free survival rates (95.0%–98.4%); TCF3–PBX1, PAX5-altered (PAX5alt), T-cell, early precursor (ETP), intrachromosomal amplification chromosome 21 (iAMP21),...

10.1158/2643-3230.bcd-20-0229 article EN Blood Cancer Discovery 2021-04-10

Subcutaneous panniculitis-like T-cell lymphoma (SPTCL) is an uncommon cutaneous that has been proposed as a distinct clinicopathologic entity, but studies of SPTCL are limited. We studied the clinicopathologic, immunophenotypic, and genetic features 11 SPTCLs. All cases had variable admixture pleomorphic small, medium, or large lymphocytes histiocytes infiltrating subcutis in lobular pattern. A granulomatous reaction was seen three erythrophagocytosis four. Karyorrhexis fat necrosis were...

10.1097/00000478-199807000-00010 article EN The American Journal of Surgical Pathology 1998-07-01

1. Ca2+ liberation induced in Xenopus oocytes by a poorly metabolized derivative of inositol 1,4,5-trisphosphate (3-deoxy-3-fluoro-D-myo-inositol 1,4,5-trisphosphate; 3-F-InsP3) was visualized using video-rate confocal microscope to image fluorescence signals reported the indicator dye calcium green-1. 2. Low (10-30 nM) intracellular concentrations 3-F-InsP3 evoked release as localized transient 'puffs'. Progressively higher (30-60 gave rise abortive waves triggered puffs, and then (> 60...

10.1113/jphysiol.1995.sp020538 article EN The Journal of Physiology 1995-02-01

The bicistronic microRNA (miRNA) locus miR-144/451 is highly expressed during erythrocyte development, although its physiological roles are poorly understood. We show that ablation in mice causes mild instability and increased susceptibility to damage after exposure oxidant drugs. This phenotype deeply conserved, as miR-451 depletion synergizes with stress cause profound anemia zebrafish embryos. At least some protective activities of stem from ability directly suppress production 14-3-3ζ, a...

10.1101/gad.1942110 article EN Genes & Development 2010-08-01

Extranodal NK/T-cell lymphoma (ENKTL), nasal type, may be of NK or T-cell origin; however, the proportion T-ENKTLs and whether they are αβ γδ type remains uncertain. To elucidate cell origin detailed phenotype ENKTL assess any clinicopathologic associations, 67 cases from Thailand were investigated, together with 5 enteropathy-associated lymphomas (EATLs) for comparison. In all, 70% receptor (TCR) β,γ and, in tested, δ negative (presumptive origin); 5% TCR γδ+, 3% αβ+, 1% αβ/γδ+, 21%...

10.1097/pas.0b013e31824433d8 article EN The American Journal of Surgical Pathology 2012-02-07

Summary We hypothesized that sirolimus, an mTOR inhibitor, may be effective in patients with autoimmune lymphoproliferative syndrome (ALPS) and treated who were intolerant to or failed other therapies. Four for cytopenias; all had a rapid complete near response. Two arthritis colitis, demonstrating marked improvement. Three resolution of lymphadenopathy splenomegaly reduction double negative T cells, population hallmark the disease. Based on these significant responses, we recommend...

10.1111/j.1365-2141.2009.07595.x article EN British Journal of Haematology 2009-02-05

New therapeutic strategies are needed for pediatric acute myeloid leukemia (AML) to reduce disease recurrence and treatment-related morbidity. The Children's Oncology Group Phase III AAML1031 trial tested whether the addition of bortezomib standard chemotherapy improves survival in patients with newly diagnosed AML. randomized younger than 30 years age de novo AML treatment or without bortezomib. All received identical backbone either four intensive courses three followed by allogeneic...

10.3324/haematol.2019.220962 article EN cc-by-nc Haematologica 2020-02-06

Patients with Down syndrome (trisomy 21, T21) have hematologic abnormalities throughout life. Newborns frequently exhibit abnormal blood counts and a clonal preleukemia. Human T21 fetal livers contain expanded erythro-megakaryocytic precursors enhanced proliferative capacity. The impact of on the earliest stages embryonic hematopoiesis is unknown nearly impossible to examine in human subjects. We modeled yolk sac using induced pluripotent stem cells (iPSCs). Blood progenitor populations...

10.1073/pnas.1211175109 article EN Proceedings of the National Academy of Sciences 2012-10-08

Purpose To characterize the toxicity, pharmacokinetics, and pharmacodynamics of selinexor, a selective inhibitor nuclear export, when combined with fludarabine cytarabine, in children relapsed or refractory leukemia. Patients Methods Eighteen patients acute leukemia were enrolled SELHEM (Selinexor With Fludarabine Cytarabine for Treatment Refractory Relapsed Leukemia Myelodysplastic Syndrome) clinical trial (NCT02212561). Selinexor, initially at 30 mg/m2 per dose, was given orally on days 1,...

10.1200/jco.2016.67.5066 article EN Journal of Clinical Oncology 2016-08-10

Bloodstream infection (BSI) is a common, life-threatening complication of treatment for cancer. Predicting BSI before onset clinical symptoms would enable preemptive therapy, but there no reliable screening test.

10.1001/jamaoncol.2019.4120 article EN cc-by-nc-nd JAMA Oncology 2019-12-19
Coming Soon ...